Acasti Pharma Inc. (ACST)
| Previous close | 2.8400 |
| Open | 2.9500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.9500 - 3.0100 |
| 52-week range | 1.7200 - 3.8400 |
| Volume | |
| Avg. volume | 26,181 |
| Market cap | 27.869M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.6800 |
| Earnings date | 21 Jun 2024 - 25 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.97 |
Insider Monkey12 Best Biotech Penny Stocks to Invest In
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]
GlobeNewswireAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission TimelinePoster Highlighting the STRIVE-ON Trial Presented at 2024 International Stroke Conference PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its n
- GlobeNewswire
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
Accepted for Presentation at the 2024 International Stroke ConferencePRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been a
